FOXP3 and type 1 diabetes mellitus: Early clinical studies utilizing polyclonally expanded autologous CD4+CD25+FoxP3+ Tregs demonstrated the safety and feasibility of this approach and supported their therapeutic potential for inhibition or delay of the destruction of pancreatic β cells in T1D patients (17, 20).